Ofatumumab in previously untreated chronic lymphocytic leukaemia. No clear advantages when added to chlorambucil.
In a trial including 447 leukaemia patients in whom fludarabine was unsuitable, adding ofatumumabto chlorambucil prolonged time to disease progression or death but did not reduce overall mortality. Adverse effects were more numerous.